Bulletin
Investor Alert

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 21, 2022, 7:59 p.m.

/zigman2/quotes/207821052/composite

$

82.00

Change

+0.48 +0.59%

Volume

Volume 25,175

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Previous close

$ 82.62

$ 81.52

Change

-1.10 -1.33%

Day low

Day high

$81.19

$87.79

Open

52 week low

52 week high

$43.86

$202.73

Open

Company Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in t...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

52.52

Price to Book Ratio

6.84

Enterprise Value to EBITDA

-43.49

Enterprise Value to Sales

211.46

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

185,878.00

Income Per Employee

-430,228.00

Receivables Turnover

17.18

Total Asset Turnover

0.11

Liquidity

Current Ratio

9.59

Quick Ratio

9.59

Cash Ratio

9.34

Profitability

Operating Margin

-235.51

Pretax Margin

-231.46

Net Margin

-231.46

Return on Assets

-26.56

Return on Equity

-33.69

Return on Total Capital

-31.96

Return on Invested Capital

-31.84

Capital Structure

Total Debt to Total Equity

7.46

Total Debt to Total Capital

6.94

Total Debt to Total Assets

5.81

Long-Term Debt to Equity

6.38

Long-Term Debt to Total Capital

5.93

Officers and Executives

Name Age Officer Since Title
Dr. John M. Leonard 62 2014 Director & Chief Medical Officer
Mr. Glenn Goddard 48 2018 Executive VP, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino 60 2019 Chief Scientific Officer & Executive VP
Dr. Eliana Clark - - Senior Vice President-Technical Operations
Dr. David Lebwohl - 2020 Chief Medical Officer & Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/03/2022 Derek Hicks
EVP, Chief Business Officer
19,118   Award at $0 per share. 0
11/05/2021 David Lebwohl
EVP, Chief Medical Officer
200   Disposition at $135.34 per share. 27,068
11/05/2021 David Lebwohl
EVP, Chief Medical Officer
548   Disposition at $134.07 per share. 73,470
11/05/2021 David Lebwohl
EVP, Chief Medical Officer
452   Disposition at $132.62 per share. 59,944
11/05/2021 David Lebwohl
EVP, Chief Medical Officer
1,200   Disposition at $131.71 per share. 158,052
11/05/2021 David Lebwohl
EVP, Chief Medical Officer
2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
250   Disposition at $130.47 per share. 32,617
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
525   Disposition at $129.83 per share. 68,160
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
225   Disposition at $129.01 per share. 29,027
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
849   Disposition at $127.81 per share. 108,510
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
551   Disposition at $126.92 per share. 69,932
10/14/2021 David Lebwohl
EVP, Chief Medical Officer
2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
10/11/2021 John Francis Crowley
Director
2,500   Disposition at $119.55 per share. 298,875
10/11/2021 John Francis Crowley
Director
2,500   Derivative/Non-derivative trans. at $18.83 per share. 47,075
10/05/2021 John Francis Crowley
Director
200   Disposition at $132.84 per share. 26,568
10/05/2021 John Francis Crowley
Director
1,846   Disposition at $131.74 per share. 243,192
10/05/2021 John Francis Crowley
Director
3,759   Disposition at $130.92 per share. 492,128
10/05/2021 John Francis Crowley
Director
2,915   Disposition at $129.88 per share. 378,600
10/05/2021 John Francis Crowley
Director
1,280   Disposition at $128.83 per share. 164,902
10/05/2021 John Francis Crowley
Director
10,000   Derivative/Non-derivative trans. at $18.83 per share. 188,300
09/24/2021 David Lebwohl
EVP, Chief Medical Officer
7,923   Derivative/Non-derivative trans. at $12.62 per share. 99,988
09/21/2021 David Lebwohl
EVP, Chief Medical Officer
2,400   Disposition at $149.81 per share. 359,544
09/21/2021 David Lebwohl
EVP, Chief Medical Officer
2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
09/07/2021 Glenn Goddard
EVP, Chief Financial Officer
3,482   Disposition at $180.12 per share. 627,177
09/07/2021 Glenn Goddard
EVP, Chief Financial Officer
3,482   Derivative/Non-derivative trans. at $14.58 per share. 50,767
09/01/2021 John M. Leonard
President and CEO; Director
44,735   Disposition at $170 per share. 7,604,950
09/01/2021 John M. Leonard
President and CEO; Director
15,985   Derivative/Non-derivative trans. at $18.3 per share. 292,525
09/01/2021 John M. Leonard
President and CEO; Director
28,750   Derivative/Non-derivative trans. at $23.46 per share. 674,475
08/31/2021 John M. Leonard
President and CEO; Director
37,833   Disposition at $155 per share. 5,864,115
08/31/2021 Glenn Goddard
EVP, Chief Financial Officer
24,800   Disposition at $160.22 per share. 3,973,456
08/31/2021 John M. Leonard
President and CEO; Director
37,833   Derivative/Non-derivative trans. at $14.58 per share. 551,605
08/31/2021 Glenn Goddard
EVP, Chief Financial Officer
1,817   Derivative/Non-derivative trans. at $14.58 per share. 26,491
08/31/2021 Glenn Goddard
EVP, Chief Financial Officer
22,983   Derivative/Non-derivative trans. at $19.27 per share. 442,882
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  2. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  3. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    6:37 a.m. Sept. 27, 2021

    - Barron's Online

  4. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    6:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  5. Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI

    4:58 a.m. Aug. 6, 2021

    - Tomi Kilgore

  6. The Best and Worst Biopharma Stock Performers So Far in 2021

    10:32 a.m. June 30, 2021

    - Barron's Online

  7. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform

    6:37 a.m. June 29, 2021

    - Tonya Garcia

  8. Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy

    10:24 a.m. June 28, 2021

    - Tonya Garcia

  9. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    8:21 a.m. June 30, 2021

    - Barron's Online

  10. First In-Vivo Gene Editing Data Look Good for Intellia

    7:40 a.m. June 28, 2021

    - Barron's Online

  11. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    7:32 a.m. May 21, 2021

    - Barron's Online

  12. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  13. Intellia Therapeutics price target raised to $106 from $39 at Raymond James

    7:50 a.m. Jan. 8, 2021

    - Tonya Garcia

  14. Loading more headlines...
/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. It's Time To Go To Cash For The Next 7 Years - 1-Year Update

    2:41 p.m. Jan. 20, 2022

    - Seeking Alpha

  2. Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

    10:46 a.m. Jan. 19, 2022

    - Zacks.com

  3. 5 Charts to Remember if the Stock Market Crashes in 2022

    6:03 a.m. Jan. 19, 2022

    - Motley Fool

  4. 11 Good And 4 Bad Reasons To Keep Holding ARK Invest

    3:42 p.m. Jan. 18, 2022

    - Seeking Alpha

  5. Is Beam Therapeutics a Good Stock to Buy Now?

    6:47 a.m. Jan. 16, 2022

    - Motley Fool

  6. "Motley Fool Money" 2022 Investing Preview

    2:00 p.m. Jan. 7, 2022

    - Motley Fool

  7. Genomic Medicine 2021: (Happy To) Turn The Page

    9:33 p.m. Jan. 4, 2022

    - Seeking Alpha

  8. 3 Healthcare Stocks That Could Rocket Higher in 2022

    11:30 a.m. Jan. 4, 2022

    - Motley Fool

  9. Better Buy: CRISPR vs. Intellia

    6:00 a.m. Jan. 3, 2022

    - Motley Fool

  10. 5 Biotech Stocks That More Than Doubled This Year

    8:09 a.m. Dec. 23, 2021

    - Zacks.com

  11. Loading more headlines...

At a Glance

Intellia Therapeutics, Inc.

40 Erie Street

Suite 130

Cambridge, Massachusetts 02139

Phone

1 8572856200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$57.99M

Net Income

$-134.23M

2020 Sales Growth

34.5%

Employees

312.00

/news/pressrelease/company/us/ntla

Press Releases on NTLA

  1. Tuesday's ETF Movers: ARKG, FPE

    12:22 p.m. Dec. 7, 2021

    - MarketNewsVideo.com

  2. Why Regeneron, Intellia Therapeutics On Sale

    5:43 a.m. Oct. 14, 2021

    - Baystreet.ca

  3. IWM, UTSL: Big ETF Inflows

    9:47 a.m. Sept. 28, 2021

    - MarketNewsVideo.com

  4. Loading more headlines...
Link to MarketWatch's Slice.